Andrew C. Orr, Joseph Saunders, Yusef Seymens, Michael A. Sellarole, Hesham Lakosha, Simon W. M. John, Nicholas G. Tolman, Cassandre Labelle-Dumais, K. Saidas Nair, Seyyedhassan Paylakhi, Wilhelmine N. deVries, Piotr Topilko, Barsh, Gregory S, Bodescot, Myriam, Department of Ophthalmology [San Francisco, CA, États-Unis], University of California [San Francisco] (UC San Francisco), University of California (UC)-University of California (UC), The Jackson Laboratory [Bar Harbor] (JAX), Department of Ophthalmology and Visual Sciences [Halifax, NS, Canada], Dalhousie University [Halifax], Institut de biologie de l'ENS Paris (IBENS), Département de Biologie - ENS Paris, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Ophthalmology [Boston, MA, États-Unis], Tufts University School of Medicine [Boston], Department of Anatomy [San Francisco, CA, États-Unis], This work was made possible in part, by NIH-NEI EY002162 - Core Grant for Vision Research, by the Research to Prevent Blindness Unrestricted Grant (UCSF, Ophthalmology) and William and Mary Greve Special Scholar award (KSN), Knight Templar Eye Foundation Career Starter Award (SP), National Eye Institute grants EY022891 (KSN), EY011721 (SWMJ), Barbara and Joseph Cohen Foundation (SWMJ). SWMJ is an investigator of Howard Hughes Medical Institute. Funding support from That Man May See Inc (KSN), Research Evaluation and Allocation Committee (REAC)-Tidemann fund (KSN), Marin Community Foundation- Kathlyn McPherson Masneri and Arno P. Masneri Fund (KSN)., University of California [San Francisco] (UCSF), University of California-University of California, Institut de biologie de l'ENS Paris (UMR 8197/1024) (IBENS), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de Biologie - ENS Paris, and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
A mismatch between optical power and ocular axial length results in refractive errors. Uncorrected refractive errors constitute the most common cause of vision loss and second leading cause of blindness worldwide. Although the retina is known to play a critical role in regulating ocular growth and refractive development, the precise factors and mechanisms involved are poorly defined. We have previously identified a role for the secreted serine protease PRSS56 in ocular size determination and PRSS56 variants have been implicated in the etiology of both hyperopia and myopia, highlighting its importance in refractive development. Here, we use a combination of genetic mouse models to demonstrate that Prss56 mutations leading to reduced ocular size and hyperopia act via a loss of function mechanism. Using a conditional gene targeting strategy, we show that PRSS56 derived from Müller glia contributes to ocular growth, implicating a new retinal cell type in ocular size determination. Importantly, we demonstrate that persistent activity of PRSS56 is required during distinct developmental stages spanning the pre- and post-eye opening periods to ensure optimal ocular growth. Thus, our mouse data provide evidence for the existence of a molecule contributing to both the prenatal and postnatal stages of human ocular growth. Finally, we demonstrate that genetic inactivation of Prss56 rescues axial elongation in a mouse model of myopia caused by a null mutation in Egr1. Overall, our findings identify PRSS56 as a potential therapeutic target for modulating ocular growth aimed at preventing or slowing down myopia, which is reaching epidemic proportions., Author summary Refractive errors mainly occur when changes in ocular size (ocular axial length) prevent light from focusing directly on the retina. Myopia (nearsightedness) is the most common form of refractive errors in which the focused image falls in front of the retina. The recent unprecedented rise in the incidence of myopia has significant implications as individuals with high myopia are at an increased risk of developing irreversible blinding conditions, including retinal detachment, macular degeneration, and glaucoma. Ocular axial growth is a key determinant of normal refractive development. Although the retina has been established as a central player involved in the regulation of ocular growth, the specific retinal cell type(s) and molecular pathways involved are poorly defined. Here, we have utilized genetic mouse models to provide significant insight into spatial and temporal requirements of the retinal factor PRSS56 in ocular size determination. Importantly, we have uncovered a previously unrecognized role for retinal Müller glia in ocular growth and demonstrated that Prss56 inactivation has translational potential to rescue axial length elongation in a mouse model of myopia. Collectively, our findings suggest that therapeutic strategies targeting PRSS56 to modulate ocular growth could have important clinical implications to prevent or slowdown the progression of myopia and associated blinding conditions in humans.